Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease IMU-856 is a new oral treatment option for ulcerative colitis and Crohn’s disease Daiichi Sakyo Co., Ltd. granted Immunic AG an exclusive option to in-license the drug development program when entering phase 1 clinical development IMU-856 uses an undisclosed new …

First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor Multiple sites have already been initiated in the US and first patient has been enrolled Several approvals for the ‘CALDOSE-1’ study from regulatory agencies have already been granted in European countries as well and Immunic expects patients to be enrolled in …

FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase 2 clinical trial (CALDOSE-1) Patients with active ulcerative colitis will be treated following randomization to multiple doses of IMU-838 or placebo Planegg-Martinsried, Germany, January 11th, 2017 – Immunic AG (Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, …

Two phase 1 studies for IMU-838 in healthy volunteers have been completed Compound was safe and well tolerated at all doses tested New dosing regimen was determined allowing safe administration of higher doses Planegg-Martinsried, Germany, December 12th, 2017 – Immunic AG (Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, today announced that it has completed its …

Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing Series A financing round now completed with an overall investment size of EUR 31.7 million (USD 37.5 million) – resulting in one of Europe’s largest series A financing rounds in the biotech industry Funding dedicated to further clinical development of …

  Series A financing round extended to EUR 21.7 Million Immunic’s investor base broadened by IBG fund which is managed by bmp Beteiligungsmanagement Expanded funding accelerates further development of IMU-838 and IMU-366 in chronic inflammatory and autoimmune diseases Planegg-Martinsried and Magdeburg, Germany, February 1st, 2017 – Immunic AG (Immunic Therapeutics), a recently founded private biotech company in Martinsried near Munich, …

Two executives with deep understanding of the immunology field, and with experience in the IMU-838/IMU-366 development programs add to the Management Board of Immunic AG – experienced biotech CFO is strengthening Immunic’s Supervisory Board Daniel Vitt joins Immunic as Chief Executive Officer (CEO) Hella Kohlhof joins Immunic as Chief Scientific Officer (CSO) Thomas Taapken joins Immunic’s Supervisory Board Planegg-Martinsried, Germany, …

Immunic acquires two promising drug development programs with validated targets known to be relevant in various immune and autoimmune diseases IMU-838: New oral treatment option for Crohn’s disease IMU-366: Potent and selective cytokine inhibitors for development in immune and autoimmune diseases Planegg-Martinsried, Germany, September 28, 2016 – Immunic AG (Immunic), a recently formed private start-up biotech company in Planegg-Martinsried near …

  One of the largest Series A biotech venture capital financings in Germany Venture capital consortium led by renowned sector investors Life Sciences Partners (LSP) and LifeCare Partners (LCP) Immunic focuses on the development of small molecule immune modulators up to clinical proof of concept Planegg-Martinsried, Germany, September 27, 2016 – Immunic AG (Immunic), a recently formed private start-up biotech …